Boehringer Ingelheim has opened a €60m ($66.8m) research building in Vienna, Austria, as the company looks to double down in the oncology therapeutics space. The building is named after Angelika ...

Boehringer Ingelheim, one of the world's leading research-oriented pharmaceutical companies, announced that an important investment in the future by opening a new Angelika Amon Research Building on ...

Inauguration of Angelika Amon research building in Vienna Sustainable research ... s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the world's leading research ...

Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost ... Boehringer’s capital investments reached EUR 6.0 billion Boehringer Ingelheim is one of the ...

The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years. An important investment in the future is the new ...

Boehringer Ingelheim is one of the world’s leading research-oriented pharmaceutical companies. The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new ...